-- Days : -- HRS : -- MIN : -- SEC

Register Now →

NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

This roundtable series explores immune checkpoint inhibitors and combination therapy for patients with unresectable or metastatic hepatocellular carcinoma in the frontline setting, as discussed by key opinion leaders at virtual live events and interviews.

Treating First-Line HCC With Immune Checkpoint Inhibition

Managing irAEs Across Frontline HCC Regimens Requires Clinical Judgment

Managing irAEs Across Frontline HCC Regimens Requires Clinical Judgment

During a live event, Amit Mahipal, MD, and participants discussed how to recognize and manage immune-related adverse events arising from combination regimens for unresectable HCC.

Nivolumab Plus Ipilimumab Emerges as a Go-To Regimen for Frontline HCC

Nivolumab Plus Ipilimumab Emerges as a Go-To Regimen for Frontline HCC

During a live event, Amit Mahipal, MD, and participants discussed first-line treatment selection for unresectable or metastatic hepatocellular carcinoma.

Interpreting Key Trial Data in the Era of IO in Advanced HCC

Interpreting Key Trial Data in the Era of IO in Advanced HCC

During a live event, Mark Yarchoan, MD and participants weighed new phase 3 immunotherapy combos for unresectable HCC, balancing survival gains, response durability, and real‑world toxicity challenges.

Analyzing Nivolumab and Ipilimumab as HCC Therapy

Analyzing Nivolumab and Ipilimumab as HCC Therapy

November 11, 2025

During a live event, Anthony B. El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC.

Diagnosis and Management of Unresectable HCC Using Clinical Criteria

Diagnosis and Management of Unresectable HCC Using Clinical Criteria

October 23, 2025

During a live event, Anthony B. El-Khoueiry, MD, discussed downstaging for transplant and evolving frontline systemic therapies in advanced HCC.

How to Respond to Toxicities of Each Combination HCC Regimen

How to Respond to Toxicities of Each Combination HCC Regimen

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination regimens for hepatocellular carcinoma.